Navigation Links
Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
Date:6/2/2009

ROCKVILLE, Md., June 2 /PRNewswire/ -- The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and Merck for Best Prophylactic Vaccine.

"This award caps a remarkable period of rapid progress and success in translating Sanaria's whole-organism, sporozoite malaria vaccine candidate from development through cGMP manufacturing and the initiation of clinical trials. It recognizes the remarkable achievements and dedication of the entire Sanaria team and our collaborators," states Stephen L. Hoffman, Sanaria's founder and CEO.

Sanaria's candidate malaria vaccine is composed of live, attenuated parasites. This unique formulation, having satisfied rigorous FDA scrutiny for safety, sterility, purity, potency, and reproducibility of manufacturing, is now undergoing clinical testing in volunteers for safety and efficacy.

About Sanaria Inc. The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is

http://www.sanaria.com.

Except for historical information, this news release contains certai
'/>"/>

SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
2. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
3. USAID Provides Malaria Assistance to Zimbabwe
4. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
5. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
10. Novel Vaccine Approach Offers Hope in Fight Against HIV
11. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... evolving set of regulations, Ethics & Compliance professionals ... according to a new survey issued today by ... services and education. An overwhelming majority of respondents ... far the most important component of E&C training ...
(Date:3/5/2015)... --  ndd Medical Technologies , a leader in innovative ... technology, announced that its EasyOne Pro® was used at ... Pulmonary Fibrosis Support Group. The clinic targeted patients with ... well as those suspected of having ILD or PF. ... square inches, EasyOne Pro provides accurate respiratory test results ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... and Phase 1b Combination Clinical Trials ... Anti-Leukemic Activity, SOUTH SAN FRANCISCO, Calif., June 16 ... two,clinical trials of the company,s lead drug candidate, voreloxin (formerly,SNS-595), ... when,used as a single agent in relapsed or refractory patients ...
... Patients Not Optimally Controlled with, Levodopa ... Hours Per Day, RESEARCH TRIANGLE PARK, N.C., ... announced the approval of Requip(R),XL(TM) (ropinirole extended-release tablets) ... and symptoms of idiopathic Parkinson,s disease. Requip XL ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 ... publishing company, created a unique ‘energy’ experiment to ... lives. , After quick ‘5 -7 ... more than 150+ countries reported their life improving ... respondents reported positive results. , According to research, ...
(Date:3/6/2015)... 2015 Dr. Mark Sowell recently returned from ... AZ. Offering programs for advanced education in the field of ... , As a visiting faculty member of this prestigious ... each time he visits Spear Education to participate in a ... “we are training only the top 10% and those willing ...
(Date:3/6/2015)... Alexandria, Virginia (PRWEB) March 06, 2015 ... today it has awarded five-year accreditation status to seven ... Committee mean that another 1.3 million people can now ... to protect and promote the health of their communities. ... protecting and improving the health of people and communities. ...
(Date:3/5/2015)... March 05, 2015 Shania Twain will ... than a decade. She has hinted that this will be ... seeing her perform one last time. She has had a ... beloved country sweetheart has millions of loyal fans around the world. ... native country, Canada, and on June 30th she will be at ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Risperdal ... in a Pennsylvania mass tort litigation currently underway ... a jury has begun hearing testimony in the ... atypical antipsychotic medication can cause gynecomastia, or male ... in question was filed on behalf of a ...
Breaking Medicine News(10 mins):Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... journal Addiction , researchers from Bowling Green State ... and substantially elevated risks for illegal drug use in ... incarcerated in the United States has sharply risen over ... to 2,250,000 in 2006. So too has the number ...
... 28, 2010 (Geneva, Switzerland) At the UN Millennium ... world leaders gathered to review progress on the eight ... ill-health by 2015. As the summit came to a ... $40bn to reach the goals, with particular emphasis on ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Sept. ... C-reactive protein (CRP) can vary among different racial and ... heart-disease risk and the value of cholesterol-lowering drugs, a ... of inflammation, and elevated levels have been linked -- ...
... , TUESDAY, Sept. 28 (HealthDay News) -- Think recess, and ... in the school day set aside for running and playing, ... life. What if your workplace started offering recess on the ... good idea but possibly one of the most solid tactics ...
... treatments for the disease or enable earlier diagnosis, say the ... Dentistry. Pancreatic cancer has the lowest survival rate of all ... stages, late diagnosis and its resistance to chemotherapy and radiation ... Research Fund found that nearly three quarters of pancreatic ...
... your ragweed allergies, according to a study from Queen,s University. ... develop ragweed allergy symptoms more quickly than others. But the ... swing, those symptom differences subside. The team, led ... medicine and microbiology & immunology, exposed 123 participants to ragweed, ...
Cached Medicine News:Health News:Father's incarceration associated with elevated risks of marijuana and other illegal drug use 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 3Health News:C-Reactive Protein Levels Vary By Race: Study 2Health News:C-Reactive Protein Levels Vary By Race: Study 3Health News:Adding Recess to the Workday Gains Backers 2Health News:Adding Recess to the Workday Gains Backers 3Health News:Adding Recess to the Workday Gains Backers 4Health News:Protein key to growth of pancreatic cancer 2
... Technologies, The UroMax Ultra ia designed ... high pressure and low profile., Refolding ... a remarkably strong material that is ... materials., Non-Compliant Balloons, A compliant balloon ...
... Fr Diameter with Two Large Working Channels; ... MICRO-6 Semi-Rigid Ureteroscope is the smallest ureteroscope ... and therapeutic procedures. The ACMI MICRO-6 Ureteroscope ... procedures with minimal or no dilation or ...
... is a self-dilating, semi-rigid autoclavable operating ureteroscope ... image bundle for an enhanced, clear image. ... to "0" diopters. The direction of view ... passage. The straight access operating channel is ...
... tip diameter of only 6.9Fr (2.3mm) ... range of 180 for and easy ... observation, a new optical system has ... (3.9mm) sheath dilator, 0.035" guidewire compatible, ...
Medicine Products: